statistiche ricercatore

Nazione	#
IT - Italia	8.899
US - Stati Uniti d'America	465
CN - Cina	97
SG - Singapore	94
SE - Svezia	63
BR - Brasile	33
DE - Germania	30
IN - India	23
VN - Vietnam	23
FR - Francia	20
GB - Regno Unito	15
NL - Olanda	15
CA - Canada	14
HK - Hong Kong	12
PL - Polonia	9
FI - Finlandia	8
AT - Austria	7
KR - Corea	7
IR - Iran	6
AE - Emirati Arabi Uniti	4
AR - Argentina	4
ES - Italia	4
IQ - Iraq	4
TH - Thailandia	4
AU - Australia	3
BD - Bangladesh	3
EC - Ecuador	3
GR - Grecia	3
JP - Giappone	3
PK - Pakistan	3
VE - Venezuela	3
IL - Israele	2
LT - Lituania	2
MX - Messico	2
NG - Nigeria	2
PH - Filippine	2
RU - Federazione Russa	2
TR - Turchia	2
UZ - Uzbekistan	2
ZA - Sudafrica	2
BB - Barbados	1
BH - Bahrain	1
BO - Bolivia	1
CO - Colombia	1
ID - Indonesia	1
IE - Irlanda	1
LU - Lussemburgo	1
MA - Marocco	1
MN - Mongolia	1
MO - Macao, regione amministrativa speciale della Cina	1
PE - Perù	1
PT - Portogallo	1
SA - Arabia Saudita	1
SK - Slovacchia (Repubblica Slovacca)	1
TT - Trinidad e Tobago	1
UY - Uruguay	1
Totale	9.915

Nome	#
Molecular-biology-driven treatment for metastatic colorectal cancer	2.717
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment	1.307
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors	1.005
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?	899
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment	815
New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression	711
Uncovering key targets of success for immunotherapy in pancreatic cancer	679
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus	623
BRCA-mutant pancreatic ductal adenocarcinoma	583
Immune Checkpoint Inhibitors in the Treatment of HCC	551
The interconnection between cellular metabolism and lymphocyte activation as a prognostic factor in patients affected by metastatic pancreatic ductal adenocarcinoma treated with gemcitabine and nab-paclitaxel as first line	58
Totale	9.948

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	431	0	0	0	0	0	120	40	64	35	70	49	53
2021/2022	900	53	48	3	25	40	82	47	101	51	91	179	180
2022/2023	2.128	240	297	200	148	169	213	99	97	151	274	157	83
2023/2024	1.655	69	49	69	92	138	296	300	135	78	82	173	174
2024/2025	3.803	1.147	1.264	316	349	176	239	166	20	24	38	21	43
2025/2026	503	106	70	82	94	80	71	0	0	0	0	0	0
Totale													9.948

UNICA IRIS Institutional Research Information System